ARTICLE | Clinical News
Ublituximab: Phase I/II started
September 28, 2015 7:00 AM UTC
TG Therapeutics began an open-label, U.S. Phase I/II trial to evaluate IV ublituximab, once-daily oral TGR-1202 and IV Keytruda pembrolizumab in about 12 patients. TG Therapeutics has exclusive, wor...